Company profile
Novartis
Diversified pharma
NVS · NYSE · Switzerland
Share price · NVS
$154.55+5.40 (+3.62%) 3M
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento
Assets
(52 total)
52Total Assets
26Approved
7Phase 3 / Filed
19Phase 1–2 / Early
20Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | PI3K-alphaSmall molecule | HR+/HER2- Breast Cancer HR+/HER2- Metastatic Breast Cancer | |
Atrasentan(Vanrafia) | Approved | Endothelin A receptorSmall molecule | Chronic Kidney Disease |
| Approved | VEGF-AAntibody fragment | Age-Related Macular Degeneration | |
| Approved | METSmall molecule | Non-Small Cell Lung Cancer | |
| Approved | Voltage-gated sodium channelSmall molecule | Epilepsy | |
| Approved | ALKSmall molecule | Non-Small Cell Lung Cancer | |
| Approved | BRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Small molecule | Non-Small Cell Lung Cancer | |
| Approved | mTOR kinase · mTOR (mTORC1) (inhibitor)Small molecule | EpilepsyHR+/HER2- Breast Cancer HR+/HER2- Metastatic Breast Cancer | |
fingolimod (Gilenya)(Gilenya) | Approved | Undisclosed / early pipeline · S1P receptor · Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)Small molecule | Multiple Sclerosis |
Inclisiran(Leqvio) | Approved | PCSK9RNA / oligonucleotide | Atherosclerotic Cardiovascular Disease |
Iptacopan(Fabhalta) | Approved | Complement Factor BSmall molecule | Chronic Kidney Disease |
| Approved | AromataseSmall molecule | HR+/HER2- Breast Cancer HR+/HER2- Metastatic Breast Cancer | |
| Approved | S1P receptorSmall molecule | Multiple Sclerosis | |
| Approved | FLT3Small molecule | Acute Myeloid Leukemia | |
Nateglinide(Starlix) | Approved | SUR1 (short-acting)Small molecule | Type 2 Diabetes |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.
Insider transactions
Research
Sign in to access ResearchUnlock insider transactions
Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.
Institutional holders
Research
Sign in to access ResearchUnlock institutional holders
Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.